Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy children and infants aged from 2 months to less than 6 years as established by medical history and clinical examination.~2. The subjects' parents/guardians are able to understand and sign the ICF.~Exclusion Criteria:~1. Age \< 2 months or ≥ 6 years.~2. For subjects \< 1 year, gestational age \< 34 weeks or birth weight \< 2200 grams.~3. Has poor venous access (for subjects in sub-study only).~4. Currently has a fever defined as ear/rectal temperature ≥ 38°C or axillary temperature ≥ 37.5 °C within 2 days before the time of planned vaccination.~5. Has had previous known exposure to EV71 or has received EV71 vaccine.~6. Has a history of herpangina or HFMD associated with enterovirus infection in the past 30 days before the date of the planned study drug vaccination.~7. Has been diagnosed with a significant neurological, pulmonary, cardiovascular, hematological, hepatic, or renal disorder.~8. Has a history of hypersensitivity to vaccines, or a history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~9. Has used any investigational/non-registered product (including drug, vaccine, or invasive medical device) within 28 days before vaccination or plan to use during the study period.~10. Has confirmed or suspected autoimmune disorder, or immunodeficiency.~11. Administration of any licensed live attenuated vaccine within 14 days before or after each study vaccination (with the exceptions of live attenuated Rotavirus vaccine via oral route).~12. Has used immunoglobulins or any blood products within 11 months before vaccination or plan to use during the whole study period.~13. Has had immunosuppressants, cytotoxic drugs, corticosteroids (including prednisolone ≥ 0.5 mg/kg/day or equivalent), or immunomodulators taken for \> 14 days within 6 months before first vaccination or plan to use before the last scheduled study visit. (Inhaled and topical steroids are allowed).~14. Has any medical or psychiatric condition, that is a contraindication to protocol participation based on the judgment of the Investigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- EV71vac (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).